MC Plus Material - 15_Overview of the FY2026 Medical Fee Revision 15. Appropriate Evaluation of Medical Technologies Page 25 - Center for Health Policy Information

SUMMARY

According to Google News reports on the medical fee revision, "MC Plus Material - 15_Overview of the FY2026 Medical Fee Revision 15. Appropriate Evaluation of Medical Technologies Page 25 - Center for Health Policy Information" has been announced. This information is relevant to the latest trends in the medical industry and serves as a reference for management decisions by hospitals, clinics, and medical corporations.

📝 EDITOR'S NOTE — A Medical M&A Perspective

Implications of the FY2026 Medical Fee Revision Overview

The overview of the FY2026 Medical Fee Revision, particularly regarding the "Appropriate Evaluation of Medical Technologies," released by the Center for Health Policy Information, is crucial for management strategy as it directly impacts the revenue structure of medical institutions. Each revision, with its changes in medical fee points and facility standards, has a direct effect on the financial performance of individual medical institutions.

Implications in the Context of M&A and Business Succession

The acceleration of such system changes suggests the potential difficulty in maintaining independent operations. Specifically, the burden of maintaining facility standards and investing in the latest medical equipment can be alleviated through mergers or group formations that pursue economies of scale. The current revision overview can serve as an impetus to consider M&A and business succession as part of broader management strategies, including stabilizing future revenue streams, securing funds for introducing new medical technologies, and leveraging regional medical collaboration promotion corporations. Building an organizational structure that benefits from economies of scale and can adapt to changes is a key consideration in business succession.

Specific Insights for Medical Institution Executives and Successors

It is essential to closely monitor the trends in medical fee revisions and incorporate their impact into management and business succession strategies from a medium to long-term perspective. In particular, mergers and group formations that leverage economies of scale can be effective options for maintaining facility standards and distributing equipment investment burdens. Furthermore, examining tax schemes, including transitions to specific medical corporations or social medical corporations, can contribute to smoother business succession. To enhance adaptability to system changes, we recommend collaborating with external experts from an early stage to develop a business succession plan tailored to your institution's current situation and future vision.

News Highlights

A summary of 25 pages from the “MC Plus Material – 15_Overview of the FY2026 Medical Fee Revision” released by the Center for Health Policy Information, focusing on 15. Appropriate Evaluation of Medical Technologies. This material suggests the policy for evaluating medical technologies in the FY2026 medical fee revision, highlighting the importance of mid-to-long-term management and succession strategies for healthcare facility managers, successors, and stakeholders, considering the revision cycle. Specifically, maintaining facility standards through economies of scale, dispersing the burden of capital investment, and utilizing tax schemes including conversion to specific medical corporations or social medical corporations may become key discussion points.

Perspective from M&A Medical Editorial Department

This material, focusing on the “Appropriate Evaluation of Medical Technologies” within the FY2026 Medical Fee Revision overview, goes beyond a mere pre-announcement of revision details. The evaluation criteria and fee setting for medical technologies directly impact the revenue structure of each healthcare facility, making them crucial items for due diligence when considering M&A. For instance, hospitals introducing and maintaining advanced medical technologies will see their valuation affected by how these technology fees are impacted by the revision and whether economies of scale through group affiliation can absorb costs. Furthermore, it suggests that smaller and medium-sized medical institutions serving regional healthcare may face difficulties in continuously providing highly specialized technologies, further increasing the necessity for business succession and collaboration.

Discussion Points Indicated by This News

Changes in the evaluation standards for medical technologies in the FY2026 revision will directly affect revenue structures and are essential factors in calculating valuation during M&A.
Maintaining facility standards and dispersing capital investment burdens through group affiliation will broaden management stabilization and business succession options for small and medium-sized medical institutions.
Transitioning to specific medical corporations or social medical corporations should be considered more concretely as a business succession scheme utilizing tax incentives.
Concerns about the continuity of specialized technology provision in regional healthcare may accelerate business restructuring through collaboration or M&A.

Practical Questions Arising from This News

How might the technology fees for our hospital’s strengths, such as [e.g., Cardiovascular Surgery, Radiation Therapy], be evaluated in this revision?
Is it possible to simulate the extent to which we can specifically benefit from economies of scale through group affiliation?
If considering conversion to a social medical corporation, what are the procedures, merits, and demerits involved?

If You Feel “Should I Consult Too?”

The impact of the FY2026 Medical Fee Revision on the evaluation of medical technologies directly relates to your institution’s profitability and future business continuity. Especially if you provide highly specialized medical services, it is necessary to meticulously analyze the impact of the revision and incorporate it into your mid-to-long-term management and succession strategies. We recommend consulting with experts to consider the optimal scheme for your institution’s current situation and future vision, including options such as group affiliation or corporate status changes.

M&A Medical (CentralMedience Inc.), as an M&A support institution certified by the Small and Medium Enterprise Agency, supports the business succession of medical corporations, hospitals, and clinics on a full success fee basis. Consultations are accepted with strict confidentiality. Free consultation here

📌 Source (Primary Information)

MC Plus Material – 15_Overview of the FY2026 Medical Fee Revision 15. Appropriate Evaluation of Medical Technologies Page 25 – Center for Health Policy Information

Source: Google News: Medical Fee Revision

Please see the original article for details

Regarding trends in medical institutions like this case,

we provide a detailed explanation of the 'Medical Succession Guide'

Read the Complete Guide →